Widening the clinical platform

hVIVO plc (LSE:HVO) is best known for human challenge trials, in which volunteers are deliberately exposed to a pathogen under controlled conditions to test vaccines and antivirals. Over the past two years it has been broadening that offer, and in August 2026 it bought CRS Berlin, a Clinical Trials unit that specialises in dermatology and women's health studies. This article examines how the Acquisition was structured, how it fits hVIVO's strategy, and what the company's latest results show.

What hVIVO does

hVIVO is an AIM-quoted clinical trials services company. It runs a Quarantine Facility in Canary Wharf, London, which it describes as the largest of its kind worldwide, for human challenge trials. It also operates CRS clinical sites in Mannheim and Kiel in Germany, which carry out early-phase clinical studies. Chief executive Yamin 'Mo' Khan leads the business, and Shaun Chilton is non-executive chair.

The CRS Berlin acquisition on 27 August 2026

On 27 August 2026, hVIVO announced the acquisition of CRS Berlin, a phase I and II clinical trials unit with 32 beds, 18 of them for intensive monitoring. The company said CRS Berlin has completed more than 350 studies, with a focus on dermatology and women's health. In 2025 it generated Revenue of €10 million and unaudited EBITDA of €0.3 million, and had a contracted orderbook of €10 million in June 2026.

The structure limits upfront cost. hVIVO paid €25,000 at the outset, with an earn-out equal to 18% of CRS Berlin's annual revenue for 2026 to 2028. The company expects gross earn-out payments of about €6 million, or roughly €4 million after deducting a €2 million pension liability. Khan said dermatology and women's health are large and strategically attractive areas of drug development. The announcement cited third-party forecasts that the dermatology contract clinical services market could reach US$9.7 billion by 2034 and the women's health market US$22.3 billion by 2036, though such projections are inherently uncertain.

Interim results and orderbook

Interim results published on 15 September 2026 showed revenue of £16.3 million for the first half, down from £24.2 million, which the company attributed to a guided second-half weighting and the timing of revenue recognition on certain client programmes. The adjusted EBITDA loss widened to £4.5 million, the loss before tax was £7.6 million and cash fell to £13.0 million. No Interim Dividend was paid, compared with 0.20p per share a year earlier.

The contracted orderbook more than doubled to £65 million at 30 June from £30 million at the end of 2025, and rose to £72 million including CRS Berlin. hVIVO signed three human challenge trial contracts, including its largest to date with ILiAD Biotechnologies, for a phase III whooping cough Vaccine trial. It guided to full-year revenue of about £47 million, including about £3 million from CRS Berlin, positive adjusted EBITDA in the second half and a low single-digit loss for the year.

Risks and points to watch

hVIVO's guidance relies on second-half revenue nearly doubling, so delays to client programmes would affect results, as deferrals into 2027 and 2028 already have. Integrating a third German site and growing in new therapeutic areas carries clear execution risk, and CRS Berlin's EBITDA Margin was thin in 2025, at about 3%. The board is also changing: chief financial officer Stephen Pinkerton is retiring, with Richard Cotton as interim finance chief, and Caroline Shaw joins as a non-executive director from 1 October 2026, replacing Elaine Sullivan.

Conclusion

hVIVO is expanding into dermatology and women's health by acquiring CRS Berlin through a revenue-linked earn-out rather than a large upfront payment, adding an established unit and its orderbook. The acquisition broadens the platform beyond challenge trials, but near-term results depend on converting a much larger orderbook into revenue during the second half.